

ASTRAZENECA PHARMA INDIA LIMITED

Regd. Office : Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st DECEMBER, 2005

Rs in lakhs (except for number of shares)

Sl	Particulars	9 months ended 30.09.2005 (Audited)	3 months ended 31.12.2005 (Audited)	Corresponding 3 months in the previous year 31.12.2004 (Audited)	Year to date figures for current year 31.12.2005 (Audited)	Previous Accounting year ended 31.12.2004 (Audited)
1	Net sales after excise duty	16,171.38	6,070.74	5,223.12	22,242.12	19,046.53
2	Service income	192.76	100.65	95.93	293.41	246.24
3	Other income	372.25	380.03	108.87	752.28	361.74
4	Total expenditure					
	(a) Decrease / (Increase) in stock-in-trade	508.35	(192.90)	(379.40)	315.45	1,104.80
	(b) Consumption of raw materials, packing material and traded goods	4,733.71	2,478.93	1,834.76	7,212.64	5,635.41
	(c) Personnel costs	2,827.55	912.83	1,209.47	3,740.38	3,385.51
	(d) Other expenditure	3,644.34	1,372.48	1,681.35	5,016.82	4,715.16
5	Financing costs / Bank charges	4.48	0.97	0.33	5.45	3.21
6	Depreciation	359.87	159.59	125.71	519.46	441.56
7	Profit before tax (1+2+3-4-5-6)	4,658.09	1,819.52	955.70	6,477.61	4,368.86
8	Provision for tax	1,568.18	577.19	520.74	2,145.37	1,899.08
9	Provision for fringe benefit tax	110.00	(7.00)	-	103.00	-
10	Deferred tax charge/ (credit)	(30.50)	(46.07)	(73.45)	(76.57)	(105.25)
11	Net profit after tax (7-8-9-10)	3,010.41	1,295.40	508.41	4,305.81	2,575.03
12	Paid-up equity share capital (Face value of Rs 10 per share)	500.00	500.00	500.00	500.00	500.00
13	Reserves excluding revaluation reserves (as per balance sheet of previous accounting year)	-	-	-	12,219.54	9,053.98
14	Basic and diluted earnings per share (not annualised)	60.21	25.91	10.17	86.12	51.50
15	Aggregate of non-promoter shareholding					
	- Number of shares	500,010	500,010	480,726	500,010	480,726
	- Percentage of shareholding	10.0002%	10.0002%	9.61%	10.0002%	9.61%

Notes :

- 1 The above statement of financial results was reviewed by the audit committee and approved by the Board of Directors of the Company at the meeting held on 23 February 2006.
- 2 The Company's sole business segment is Healthcare. Capital employed as on 31 December 2005, in this segment is Rs 12,719.54 lakhs (previous year ended 31 December 2004: Rs 9,553.98 lakhs).
- 3 There was 1 investor complaint pending due to dispute on ownership of shares as at the beginning of the quarter. The Company received 3 investor complaints during the quarter ended 31 December 2005. All investor complaints have been resolved satisfactorily, except for 1 unresolved complaint carried forward from the previous quarter.
- 4 Based on the favourable order passed by the Commissioner of Income Tax - Appeals dated 15 June 2005, provision for wealth tax amounting to Rs 12,164,400 created in the previous year has been reversed during the quarter ended 30 June 2005.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary to conform to the current period's presentation.
- 6 The Board of Directors in their meeting held on 23 February 2006, have recommended Rs. 20 (Previous year Rs. 50) as dividend per equity shares of Rs 10 each for the year ended 31 December 2005

**By Order of the Board of Directors
For ASTRAZENECA PHARMA INDIA LIMITED**

**Place : Bangalore
Dated : 23 February 2006**

**BHASKER V IYER
Managing Director**